<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905667</url>
  </required_header>
  <id_info>
    <org_study_id>221-005</org_study_id>
    <nct_id>NCT04905667</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®</brief_title>
  <official_title>A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, blind, parallel controlled clinical trial. The primary&#xD;
      objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2&#xD;
      monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult&#xD;
      volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and&#xD;
      Herceptin ®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will enroll in random order, and be divided into two groups, then receive a single&#xD;
      dose (6 mg/kg) of GB221 or Herceptin ®, and accept observation for 42 days. Throughout the&#xD;
      course, safety data will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Actual">September 11, 2020</completion_date>
  <primary_completion_date type="Actual">September 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic AUC0-t parameters of GB221 and Herceptin ®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic AUC0-∞parameters of GB221 and Herceptin ®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic Cmax parameters of GB221 and Herceptin ®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic Tmax parameters of GB221 and Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic t1/2 parameters of GB221 and Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic CL parameters of GB221 and Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic Vd parameters of GB221 and Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the pharmacokinetic Ke parameters of GB221 and Herceptin ®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the incidence of ADA in of GB221 and Herceptin ® group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nab</measure>
    <time_frame>Day 43</time_frame>
    <description>compare the incidence of Nab in of GB221 and Herceptin ® group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GB221 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg, single dose, intravenous infusion, 90-100 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mg/kg, single dose, intravenous infusion, 90-100 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB221</intervention_name>
    <description>6 mg/kg, single dose, intravenous infusion, 90-100 min</description>
    <arm_group_label>GB221 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>6 mg/kg, single dose, intravenous infusion, 90-100 min</description>
    <arm_group_label>Herceptin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Signed informed consent form;&#xD;
&#xD;
          -  2. Healthy adult volunteers aged between 18 and 45, male or female;&#xD;
&#xD;
          -  3. Medical examination as required within 28 days, body mass index (BMI) 19.0 ~ 24.0,&#xD;
             weight≥50 kg for men, ≥45 kg for women, and≤ 75 kg for both;&#xD;
&#xD;
          -  4. Agreed with taking reliable contraceptive measures, and no fertility planning from&#xD;
             the beginning to the end of the study within 6 months;&#xD;
&#xD;
          -  5.Subject can communicate well with the investigators and complete the study according&#xD;
             to the study regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant or lactating women, or positive in either blood or urine pregnancy test;&#xD;
             or unwilling to take effective contraceptive measures during the trial and within 6&#xD;
             months after the end of the trial at fertile age;&#xD;
&#xD;
          -  2. Allergic constitution; or history of allergic to experimental drug ingredient or&#xD;
             any drug or food or pollen; or abnormal serum immunoglobulin E (IgE) test;&#xD;
&#xD;
          -  3. History of drug abuse, or positive urine test for drug;&#xD;
&#xD;
          -  4. History of the central nervous system, cardiovascular system, kidney, liver,&#xD;
             digestive system, respiratory system, metabolic system or other significant diseases.&#xD;
             History of high blood pressure, or clinically significant systolic blood pressure≥140&#xD;
             mmHg/diastolic blood pressure≥90 mmHg;&#xD;
&#xD;
          -  5. Family history of cancer, or tumor markers (male: CEA, AFP, PSA, CA-125; Female:&#xD;
             CEA, AFP, CA-153, CA-125) positive.&#xD;
&#xD;
          -  6. Participated in other clinical trials of drug or used drugs harmful to major organs&#xD;
             within 3 months;&#xD;
&#xD;
          -  7. Blood donation within 3 months;&#xD;
&#xD;
          -  8. Used prescription or OTC drugs within 14 days;&#xD;
&#xD;
          -  9. Left ventricular ejection fraction (LVEF) &lt; 60%;&#xD;
&#xD;
          -  10. ALT or AST &gt; 1.5 ULN, Cr &gt; ULN;&#xD;
&#xD;
          -  11. WBC &lt; 0.8 LLN or &gt; 1.2 ULN; ANC &lt; 0.8 LLN; PLT &lt; 0.8 LLN; HGB &lt; 0.9LLN.&#xD;
&#xD;
          -  12. HBs-Ag, HCV-Ab, anti-HIV or TP-Ab positive;&#xD;
&#xD;
          -  13. Anti-drug antibody (ADA) test positive;&#xD;
&#xD;
          -  14.History of psychosis;&#xD;
&#xD;
          -  15. History of postural hypotension;&#xD;
&#xD;
          -  16. More than 5 cigarettes per day;&#xD;
&#xD;
          -  17. More than 28 units of alcohol per week; Or alcohol breath test positive within 24&#xD;
             hours before pre-dose;&#xD;
&#xD;
          -  18. History of dizziness of blood or needle;&#xD;
&#xD;
          -  19. Unsuitable for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>510799</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>anti-HER-2 human monoclonal antibody</keyword>
  <keyword>Herceptin</keyword>
  <keyword>GB221</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

